Cytori Announces New Annual Stockholders Meeting Date for June 18
May 30 2019 - 4:15PM
Cytori Therapeutics, Inc. (Nasdaq: CYTX) today announced that it
convened its annual meeting of stockholders on Tuesday, May 28,
2019 and adjourned the meeting until Tuesday, June 18, 2019, at
9:00 a.m., Pacific Time. The annual meeting was adjourned to allow
the Company’s stockholders an additional opportunity to evaluate
Proposal 4, relating to the approval of a reverse stock split of
the Company’s common stock. Although more than 64% of the
votes cast were in favor of the reverse stock split (Proposal 4),
approval requires the affirmative vote of a majority of the
outstanding shares of common stock.
The annual meeting was adjourned until 9:00
a.m., Pacific Time, on June 18, 2019 at 3020 Callan Road, San
Diego, California 92121, the Company’s headquarters and the
original location of the annual meeting. The record date for the
annual meeting remains March 29, 2019. Stockholders that have yet
to vote are requested to do so prior to the new June 18 meeting
date and are encouraged to vote in favor of the reverse stock split
as outlined in the Company’s proxy materials.
Stockholders who have previously sent in proxy
cards or given instructions to brokers do not need to re-cast their
votes unless they want to change their vote. Proxies
previously submitted in respect of the meeting will be voted at the
adjourned meeting unless properly revoked.
If stockholders have questions, need help voting shares, or want
to change a vote in favor of Proposal 4, please call the voting
center at (289) 695-3947.
About Cytori
Therapeutics, Inc.
Cytori is developing, manufacturing, and
commercializing nanoparticle-delivered oncology drugs. Cytori
is focused on the liposomal encapsulation of anti-neoplastic
chemotherapy agents or other drugs which may enable the effective
delivery of the agents to target sites while reducing systemic
toxicity and improving pharamacokinetics. Cytori’s pipeline
consists of ATI-0918 pegylated liposomal doxorubicin hydrochloride
for breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s
sarcoma, a complex/hybrid generic drug, and ATI-1123 patented
albumin-stabilized pegylated liposomal docetaxel for multiple solid
tumors. For more information, please visit ir.cytori.com.
Cytori Therapeutics, Inc.
Gary Titus, +1 (858) 458.0900ir@cytori.com
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Sep 2023 to Sep 2024